MET and neoplasm: Anti‐angiogenic TKIs can normalize tumor vasculature, enhance T effector cell infiltration, and reduce immunosuppressive myeloid cells, while MET inhibition may further modulate antitumor immunity via VEGF‐axis regulation and macrophage activation [58].